Brett Hale Sells 24,188 Shares of Hyperfine (NASDAQ:HYPR) Stock

Hyperfine, Inc. (NASDAQ:HYPR) CFO Brett Hale sold 24,188 shares of the stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $1.21, for a total value of $29,267.48. Following the completion of the transaction, the chief financial officer directly owned 275,812 shares in the company, valued at approximately $333,732.52. This represents a 8.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hyperfine Price Performance

HYPR stock traded up $0.02 during mid-day trading on Wednesday, hitting $1.17. 352,549 shares of the stock were exchanged, compared to its average volume of 502,890. The business has a fifty day moving average price of $1.16 and a 200 day moving average price of $1.20. Hyperfine, Inc. has a 12 month low of $0.53 and a 12 month high of $2.22. The stock has a market capitalization of $113.69 million, a price-to-earnings ratio of -2.66 and a beta of 1.09.

Hyperfine (NASDAQ:HYPR) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.02. The firm had revenue of $5.29 million for the quarter, compared to analyst estimates of $5.30 million. Hyperfine had a negative return on equity of 95.09% and a negative net margin of 262.29%. As a group, equities analysts forecast that Hyperfine, Inc. will post -0.57 EPS for the current fiscal year.

Analyst Ratings Changes

HYPR has been the topic of several research reports. Lake Street Capital lifted their price target on shares of Hyperfine from $2.00 to $2.50 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Hyperfine to a “hold” rating in a report on Thursday, March 19th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Hyperfine has a consensus rating of “Hold” and an average target price of $1.45.

Institutional Investors Weigh In On Hyperfine

Several institutional investors have recently bought and sold shares of HYPR. EP Wealth Advisors LLC purchased a new position in Hyperfine in the 4th quarter worth approximately $34,000. XTX Topco Ltd grew its holdings in shares of Hyperfine by 47.9% in the fourth quarter. XTX Topco Ltd now owns 80,735 shares of the company’s stock worth $79,000 after purchasing an additional 26,165 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Hyperfine in the fourth quarter worth $55,000. Catalio Capital Management LP raised its holdings in Hyperfine by 92.8% during the 4th quarter. Catalio Capital Management LP now owns 1,320,041 shares of the company’s stock valued at $1,293,000 after buying an additional 635,500 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in Hyperfine by 50.2% during the 4th quarter. Bridgeway Capital Management LLC now owns 119,700 shares of the company’s stock valued at $117,000 after buying an additional 40,000 shares during the period. 15.03% of the stock is currently owned by hedge funds and other institutional investors.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on expanding access to advanced neuroimaging through its portable magnetic resonance imaging (MRI) system. The company’s flagship product, Swoop®, is designed to enable bedside MRI scanning in a wide range of clinical environments, including emergency departments, intensive care units and outpatient clinics. By leveraging a compact, high-performance permanent magnet and a custom-designed gradient system, Hyperfine aims to reduce the logistical and financial barriers associated with traditional, large-scale MRI installations.

The Swoop system features a lightweight, wheeled design that can be maneuvered directly to a patient’s bedside, allowing clinicians to conduct diagnostic imaging without the need to transport critically ill or immobile patients.